HK1137419A1 - Tartrate derivatives for use as coagulation factor ixa inhibitors - Google Patents

Tartrate derivatives for use as coagulation factor ixa inhibitors

Info

Publication number
HK1137419A1
HK1137419A1 HK10101264.5A HK10101264A HK1137419A1 HK 1137419 A1 HK1137419 A1 HK 1137419A1 HK 10101264 A HK10101264 A HK 10101264A HK 1137419 A1 HK1137419 A1 HK 1137419A1
Authority
HK
Hong Kong
Prior art keywords
factor ixa
coagulation factor
ixa inhibitors
tartrate derivatives
tartrate
Prior art date
Application number
HK10101264.5A
Other languages
English (en)
Inventor
Henning Steinhagen
Markus Follmann
Jochen Goerlitzer
Herman Schreuder
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of HK1137419A1 publication Critical patent/HK1137419A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/60—Two oxygen atoms, e.g. succinic anhydride
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
HK10101264.5A 2006-09-13 2010-02-04 Tartrate derivatives for use as coagulation factor ixa inhibitors HK1137419A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006042927 2006-09-13
PCT/EP2007/007612 WO2008031508A1 (fr) 2006-09-13 2007-08-31 Dérivés de tartrate utilisés comme inhibiteurs du facteur de coagulation ixa

Publications (1)

Publication Number Publication Date
HK1137419A1 true HK1137419A1 (en) 2010-07-30

Family

ID=38720737

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10101264.5A HK1137419A1 (en) 2006-09-13 2010-02-04 Tartrate derivatives for use as coagulation factor ixa inhibitors

Country Status (23)

Country Link
US (1) US8263621B2 (fr)
EP (1) EP2069288B1 (fr)
JP (1) JP5249225B2 (fr)
KR (1) KR20090053813A (fr)
CN (1) CN101516833B (fr)
AR (1) AR062744A1 (fr)
AU (1) AU2007297012B2 (fr)
BR (1) BRPI0716778A2 (fr)
CA (1) CA2663543A1 (fr)
CL (1) CL2007002651A1 (fr)
CO (1) CO6220943A2 (fr)
HK (1) HK1137419A1 (fr)
IL (1) IL197505A0 (fr)
MA (1) MA30706B1 (fr)
MX (1) MX2009001990A (fr)
MY (1) MY148254A (fr)
NO (1) NO20091106L (fr)
NZ (1) NZ575604A (fr)
RU (1) RU2446160C2 (fr)
TW (1) TWI406852B (fr)
UY (1) UY30586A1 (fr)
WO (1) WO2008031508A1 (fr)
ZA (1) ZA200900806B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101209976B (zh) * 2006-12-29 2012-01-11 中国人民解放军军事医学科学院毒物药物研究所 取代的酒石酸衍生物及其用于制备β-分泌酶抑制剂的用途
TW201033184A (en) 2008-12-05 2010-09-16 Mochida Pharm Co Ltd Morpholinone compounds as factor IXa inhibitors
US8987242B2 (en) 2008-12-05 2015-03-24 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXA inhibitors
JP5841547B2 (ja) * 2010-02-11 2016-01-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害剤としてのマクロ環
EP3131897B8 (fr) 2014-04-16 2022-08-03 Merck Sharp & Dohme LLC Inhibiteurs du facteur ixa

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3731542A1 (de) 1987-09-17 1989-03-30 Schering Ag Neue dicarbonsaeure-bis(3,5-dicarbamoyl-2,4,6-triiod-anilide), verfahren zu deren herstellung sowie diese enthaltende roentgenkontrastmittel
RU2043344C1 (ru) * 1991-05-20 1995-09-10 Курский Государственный Медицинский Институт N-2-(1- r1-5-r2-6-r3- бензимидазолил)сукцинаминовые кислоты, проявляющие нейролептическую, антигипоксическую и антиаритмическую активность
WO1994022885A1 (fr) 1993-03-29 1994-10-13 Queen's University At Kingston Composes anticoagulants
EP1332131A2 (fr) 2000-11-07 2003-08-06 Bristol-Myers Squibb Company Derives d'acide utiles comme inhibiteurs de serines proteases
DE10104598A1 (de) 2001-02-02 2002-08-08 Boehringer Ingelheim Pharma Carbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
US20020151595A1 (en) 2001-02-02 2002-10-17 Ries Uwe Joerg Carboxylic acid amides having antithrombotic activity
US7122559B2 (en) 2003-02-11 2006-10-17 Bristol-Myers Squibb Company Phenylglycine derivatives useful as serine protease inhibitors
US7638513B2 (en) * 2004-06-02 2009-12-29 Schering Corporation Compounds for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
JP5249225B2 (ja) 2013-07-31
TWI406852B (zh) 2013-09-01
BRPI0716778A2 (pt) 2014-04-22
AU2007297012B2 (en) 2011-12-22
NO20091106L (no) 2009-06-09
ZA200900806B (en) 2009-12-30
KR20090053813A (ko) 2009-05-27
TW200829557A (en) 2008-07-16
AR062744A1 (es) 2008-12-03
EP2069288A1 (fr) 2009-06-17
CA2663543A1 (fr) 2008-03-20
JP2010503624A (ja) 2010-02-04
MA30706B1 (fr) 2009-09-01
CL2007002651A1 (es) 2008-02-08
RU2446160C2 (ru) 2012-03-27
EP2069288B1 (fr) 2014-03-26
RU2009113616A (ru) 2010-10-20
US8263621B2 (en) 2012-09-11
US20090233961A1 (en) 2009-09-17
UY30586A1 (es) 2008-05-02
NZ575604A (en) 2011-12-22
MY148254A (en) 2013-03-29
WO2008031508A1 (fr) 2008-03-20
CN101516833A (zh) 2009-08-26
MX2009001990A (es) 2009-03-06
AU2007297012A1 (en) 2008-03-20
IL197505A0 (en) 2009-12-24
CN101516833B (zh) 2013-04-03
CO6220943A2 (es) 2010-11-19

Similar Documents

Publication Publication Date Title
MY150745A (en) Isoserine derivatives for use as coagulation factor ixa inhibitors
HK1135103A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
EA200970447A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
EA200901486A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ, КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR
WO2008060907A3 (fr) Nouveaux inhibiteurs de la kinase
SG178591A1 (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
EA201170521A1 (ru) Новые соединения
EA200800564A1 (ru) Производные ксантина как селективные агонисты нм74а
TW200637860A (en) Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same
GEP20115342B (en) New diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them
EA200901484A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR
TW200801032A (en) Azaheterocyclyl derivatives of androstanes and androstenes as medicaments for cardiovascular disorders
HK1137419A1 (en) Tartrate derivatives for use as coagulation factor ixa inhibitors
MX347620B (es) Derivados de sulfonilaminopirrolidinona, su preparacion y aplicacion terapeutica.
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure
MY148732A (en) Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
WO2009097973A3 (fr) Imidazopyridazines en tant qu'inhibiteurs de par1, leur production et leur utilisation en tant que médicaments
ATE496899T1 (de) Tetrahydro- und dihydrochinazolinone
SMT201300112B (it) Sale citrato di 9E-15-(2-pirrolidin-1-il-etossi)-7,12,25-triossa-19,21,24-triaza-tetracicloÄ18.3.1.1(2,5).1(14,18)Üesacos a-1(24),2,4,9,14,16,18(26),20,22-nonaene
MY152040A (en) Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
MX2007010841A (es) 8-pirrolidinobenzimidazoles biciclicos sustituidos, un metodo para su produccion y su uso como medicamentos.
ATE553088T1 (de) Substituierte chinolone ii
UA92908C2 (ru) Соединения, производные от 5-тиоксилозы, и их терапевтическое применение

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170831